Publications by authors named "Neus LLarch"

Claim this Profile
S
Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma.
Jean-Charles Nault, Claudia Campani, Theo Z Hirsch, Ethan Neumann, Waqar Arif, Neus Llarch

medRxiv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update.
Maria Reig, Marco Sanduzzi-Zamparelli, Alejandro Forner, Jordi Rimola, Joana Ferrer-Fàbrega, Neus Llarch

J Hepatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to" Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes," [Eur J Cancer 2025 May 15:221:115404.].
Marta Fortuny, Marta García-Calonge, Óscar Arrabal, Marco Sanduzzi-Zamparelli, Andrés Castaño-García, Neus Llarch

Eur J Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages.
Carla Fuster-Anglada, Josep Corominas, Aida Marsal, Neus Llarch, Gemma Iserte

Front Immunol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes.
Marta Fortuny, Marta García-Calonge, Óscar Arrabal, Marco Sanduzzi-Zamparelli, Andrés Castaño-García, Neus Llarch

Eur J Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer risk.
Núria Granel, Gemma Iserte, Concepció Bartres, Neus Llarch, Anna Pla

BMC Gastroenterol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges in Liver Transplantation for Hepatocellular Carcinoma: A Review of Current Controversies.
Ezequiel Mauro, Marco Sanduzzi-Zamparelli, Gabrielle Jutras, Raquel Garcia, Alexandre Soler Perromat, Neus Llarch

Cancers (Basel)· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients-A Multiparametric Prediction.
Sergio Muñoz-Martínez, Victor Sapena, Ángeles García-Criado, Anna Darnell, Alejandro Forner, Neus Llarch

Cancers (Basel)· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis.
Ismael El Hajra, Marco Sanduzzi-Zamparelli, Víctor Sapena, Sergio Muñoz-Martínez, Ezequiel Mauro, Neus Llarch

Hepatology· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
Marco Sanduzzi-Zamparelli, Zoe Mariño, Sabela Lens, Victor Sapena, Gemma Iserte, Neus Llarch

J Hepatol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current pharmacological treatment of hepatocellular carcinoma.
Sergio Muñoz-Martínez, Gemma Iserte, Marco Sanduzzi-Zamparelli, Neus Llarch, Maria Reig

Curr Opin Pharmacol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs.
Álvaro Díaz-González, Víctor Sapena, Loreto Boix, Ferrán Torres, Marco Sanduzzi-Zamparelli, Neus LLarch

United European Gastroenterol J· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma.
Álvaro Díaz-González, Ernest Belmonte, Víctor Sapena, Marco Sanduzzi-Zamparelli, Anna Darnell, Neus Llarch

J Clin Gastroenterol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma.
Josep Corominas, Victor Sapena, Marco Sanduzzi-Zamparelli, Cristina Millán, Esther Samper, Neus Llarch

Cancers (Basel)· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid.
Jordi Rimola, Anna Darnell, Ernest Belmonte, Victor Sapena, Carla Caparroz, Neus Llarch

Eur Radiol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials.
Álvaro Díaz-González, Víctor Sapena, Loreto Boix, Mercè Brunet, Ferrán Torres, Neus LLarch

Liver Int· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
Jordi Rimola, Alejandro Forner, Víctor Sapena, Neus Llarch, Anna Darnell

Eur Radiol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules ≤2 cm in cirrhosis.
Carmen Ayuso, Alejandro Forner, Anna Darnell, Jordi Rimola, Ángeles García-Criado, Neus Llarch

Liver Int· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib.
Álvaro Díaz-González, Marco Sanduzzi-Zamparelli, Víctor Sapena, Ferran Torres, Neus LLarch

Aliment Pharmacol Ther· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.
Maria Reig, Ferran Torres, Carlos Rodriguez-Lope, Alejandro Forner, Neus LLarch

J Hepatol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design.
Maria Reig, Jordi Rimola, Ferran Torres, Anna Darnell, Carlos Rodriguez-Lope, Neus Llarch

Hepatology· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis